# VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD (CURG) **Page:** https://fundology.uk/fund/curg · ISIN IE000B9PQW54 ## At a glance > Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise. As of 13/11/2026, CURG (VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD, ISIN IE000B9PQW54) closed at £20.36 on the London Stock Exchange. Its ongoing charge is 0.35% a year (about £35 on £10,000). Over the three years to 13/11/2026 its price changed by +51.7%, or +37.0% after UK CPIH inflation. ## Summary VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD is an exchange-traded fund (ETF) from VanEck, launched in 2022. It tracks the MVIS Global Future Healthcare ESG Index - Benchmark TR Net. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. Latest close: **£20.36** (13/11/2026). ## Key facts | Fact | Value | |---|---| | Ticker (LSE) | CURG | | ISIN | IE000B9PQW54 | | Also listed as | CURE (London Stock Exchange, US dollars) | | Category | Healthcare | | Type | ETF | | Provider | VanEck | | Tracks | MVIS Global Future Healthcare ESG Index - Benchmark TR Net | | Income | Accumulating | | Ongoing charge | 0.35% a year (£35 per £10,000) | | Fund size | £18.7m | | Launched | 2022 | | Domicile | Ireland | | UK reporting fund status | Yes — on HMRC’s list of reporting funds (list of 02/11/2026); reporting fund since 02/09/2022 | ## Past returns (periods to 13/11/2026) After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after UK CPIH inflation. | Window | Return | After CPIH inflation | Measured as | |---|---|---|---| | 1 year | +20.77% | +16.50% | income reinvested | | 3 years | +51.65% | +37.01% | price only | Returns: as reported (delayed data) and worked out from recorded daily closes. Inflation: UK CPIH, latest month published. ## Calendar-year returns Calendar-year returns of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD in pounds (price, with income reinvested in the fund): 2023 −8.5%, 2024 −2.4%, 2025 +7.3%; 2026 to 13/11/2026 +22.7%. Returns of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +32.4%; to 30/09/2025: +9.1%; to 30/09/2024: −1.2%; to 30/09/2023: −15.0%. | Year | Return | After CPIH inflation | Measured as | |---|---|---|---| | 2023 | -8.5% | -12.2% | Price | | 2024 | -2.4% | -5.7% | Price | | 2025 | +7.3% | +3.6% | Price | | 2026 to 13/11/2026 | +22.7% | +18.8% | Price | ## Risk metrics | Window | Volatility | Max drawdown | |---|---|---| | 1 year | 29.14% | -17.48% | | 3 years | 22.40% | -24.04% | ## Largest fall Volatility of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD in pounds, annualised from weekly returns to 13/11/2026: 29.1% over 1 year, 22.4% over 3 years. Largest fall in the price of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD since September 2022, in pounds: −33.0% from 09/09/2022 to 11/04/2025. The lowest 12-month return of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD in pounds (price, with income reinvested in the fund) since September 2022 was −26.3% (12 months to 10/11/2023); the highest was +31.7% (12 months to 09/10/2026). On 13/11/2026 the price of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD was 6.2% below its highest weekly close since September 2022 (30/10/2026), in pounds. ## Charges compared with similar funds Ongoing charge of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD 0.35% a year. Compared on 14/11/2026, 11 of the 28 other healthcare funds charge more, 3 the same and 14 less (share classes counted once). ## Funds tracking the same index 2 funds track MVIS Global Future Healthcare ESG Index - Benchmark TR Net, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.45% a year (13/11/2026). | Fund | Ongoing charge | 1 year | 3 years | 5 years | |---|---|---|---|---| | VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD (this fund) | 0.35% | +20.8% | — | — | | VanEck Sustainable Future of Food UCITS ETF Accum A USD | 0.45% | -2.6% | — | — | Returns are as reported, in pounds, income reinvested unless marked "(price)". ## Charges & eligibility - Ongoing charges figure (OCF): **0.35%** per year (as of 13/11/2026) - Stocks and shares ISA eligible: usually (check with your platform) - SIPP eligible: usually (check with your provider) - ISA and SIPP mean the kind of product usually qualifies under HMRC rules. We do not check each platform’s list — each provider decides which funds it offers. Crypto ETNs have not qualified for a stocks and shares ISA since 06/04/2026, and overseas funds that are not UK-recognised UCITS, such as Swiss ETFs, do not usually qualify. ## What it holds As of 13/11/2026, CURG holds 50 positions, according to its published holdings. The largest is Moderna at 11.16% of the fund; the ten largest make up 61.6%. ### Top holdings Largest positions (as of 13/11/2026), as a percentage of the whole fund: | # | Holding | Ticker | Weight | |---|---|---|---| | 1 | Moderna | [MRNA](https://fundology.uk/stock/MRNA) | 11.16% | | 2 | Regeneron Pharmaceuticals | [REGN](https://fundology.uk/stock/REGN) | 9.16% | | 3 | Vertex Pharmaceuticals | [VRTX](https://fundology.uk/stock/VRTX) | 8.00% | | 4 | Veeva Systems | [VEEV](https://fundology.uk/stock/VEEV) | 7.27% | | 5 | Natera | [NTRA](https://fundology.uk/stock/NTRA) | 5.61% | | 6 | DexCom | [DXCM](https://fundology.uk/stock/DXCM) | 5.29% | | 7 | Illumina | [ILMN](https://fundology.uk/stock/ILMN) | 4.89% | | 8 | Guardant Health | [GH](https://fundology.uk/stock/GH) | 4.06% | | 9 | BioNTech | [BNTX](https://fundology.uk/stock/BNTX) | 3.39% | | 10 | Alnylam Pharmaceuticals | [ALNY](https://fundology.uk/stock/ALNY) | 2.79% | ## Where it invests Shares of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed. ### By sector Added up from the fund’s published holdings, as of 06/11/2026. | Sector | Weight | |---|---| | Health Care | 97.0% | | Consumer Staples | 3.0% | ### By country Added up from the fund’s published holdings, as of 06/11/2026. | Country | Weight | |---|---| | United States | 85.5% | | China | 4.2% | | Germany | 3.4% | | Australia | 2.3% | | Japan | 1.3% | | Sweden | 1.2% | | Switzerland | 1.2% | | United Kingdom | 0.5% | | Other countries | 0.5% | All 50 holdings: https://fundology.uk/fund/curg/holdings ## Questions people ask **What is the ongoing charge of CURG?** The ongoing charge of CURG is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD 0.35% a year. Compared on 14/11/2026, 11 of the 28 other healthcare funds charge more, 3 the same and 14 less (share classes counted once). **What does CURG track?** CURG tracks the MVIS Global Future Healthcare ESG Index - Benchmark TR Net. **Is CURG accumulating or distributing?** CURG is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. **What is the ISIN of CURG?** The ISIN of CURG is IE000B9PQW54. An ISIN identifies one exact share class of a fund; CURG is its ticker on the London Stock Exchange. The same share class is also listed as CURE (London Stock Exchange, US dollars). **What does CURG hold?** As of 13/11/2026, CURG holds 50 positions, according to its published holdings. The largest is Moderna at 11.16% of the fund; the ten largest make up 61.6%. Its ten largest holdings are Moderna (11.16%), Regeneron Pharmaceuticals (9.16%), Vertex Pharmaceuticals (8.00%), Veeva Systems (7.27%), Natera (5.61%), DexCom (5.29%), Illumina (4.89%), Guardant Health (4.06%), BioNTech (3.39%) and Alnylam Pharmaceuticals (2.79%). **What were CURG’s returns in each of the last five years?** Calendar-year returns of CURG in pounds (price, with income reinvested in the fund): 2023 −8.5%, 2024 −2.4%, 2025 +7.3%; 2026 to 13/11/2026 +22.7%. Past performance is not a guide to future returns. **How has CURG done after inflation?** Over the three years to 13/11/2026 CURG’s price changed by +51.7%, or +37.0% after UK CPIH inflation. Past performance is not a guide to future returns. --- We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments. Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.